Is Ascendis Pharma's share price accurately reflecting its discounted cash flow and pipeline progress?

Ascendis Pharma's share price closed at US$208.76, with a 1-year return of 58.7%. The Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 77.8%. However, the valuation checklist scores 4 out of 6, indicating some areas where the stock is attractively priced and others where it is more fully valued.